---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-007447"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:17:22.720963+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# FDA accepts brepocitinib NDA for dermatomyositis, grants Priority Review; PDUFA Q3 2026

## Summary
- FDA accepted NDA and granted Priority Review for brepocitinib in dermatomyositis; PDUFA target action date in Q3 2026.
- Launch expected at end of September 2026 if approved; supported by positive Phase 3 VALOR trial (N=241).
- VALOR was first positive 52-week placebo-controlled study in dermatomyositis; brepocitinib 30mg met primary endpoint and all nine key secondary endpoints.
- If approved, brepocitinib would be first targeted therapy for dermatomyositis; safety profile similar to approved JAK/TYK2 inhibitors.

## SEC filing metadata
- accession: 0001140361-26-007447
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036126007447/0001140361-26-007447-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036126007447/ef20066998_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-007447
- JSON: https://secwatch.observer/filing/0001140361-26-007447.json
- Plain text: https://secwatch.observer/filing/0001140361-26-007447.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.